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ABSTRACT
Objective: The main objective of the current research is focused in discovering the best polyethylene glycol (PEG) as solid dispersion carrier using 
etoricoxib (ECB) as a model drug.
Methods: Varieties of PEG, namely PEG - 3350, PEG - 4000, PEG - 6000, PEG - 8000, and PEG - 20000, were evaluated as a carrier for making ECB solid 
dispersions. ECB:PEG was taken in the ratios of 1:1, 1:2, 1:4, and 1:6. The solid dispersions were prepared by microwave fusion method and compressed 
using 8 station tablet compression machine. The fabricated solid dispersion tablets were tested for physicochemical characteristics and drug release 
rates. The release of ECB from the prepared solid dispersions was further analyzed kinetically using the first order and Hixson-Crowell’s plots.
Results: All the solid dispersion batches were shown satisfactory physicochemical characteristics. ECB solid dispersion batches with PEG - 6000 
showed good solubility in distilled water (up to 2.29±0.01 µg/ml) and in 0.1 N HCl (up to 2.18±0.01 µg/ml) when compared with ECB alone 
(0.21±0.01 µg/ml and 0.32±0.01 µg/ml). The prepared solid dispersions with PEG 6000 are shown good ECB release.
Conclusion: Among PEG carriers, PEG - 6000 was found to be the best carrier for increasing the solubility and release rate of ECB form the solid 
dispersions compared to PEG - 3350, PEG - 4000, PEG - 8000, and PEG - 20000.
Keywords: Etoricoxib, Polyethylene glycol, Solid dispersions, Evaluation.
INTRODUCTION
The industrial pharmacist makes so many trials with the aim to increase 
the solubility of poorly water-soluble drugs in an inexpensive way. 
Among the different techniques of increasing solubility, solid dispersion 
technique was attaining the fame [1].
Etoricoxib (ECB) is a nonsteroidal drug used in dealing with all the 
varieties of pain and arthritic inflammation. ECB is a poorly water-
soluble drug with 92% protein binding and poor bioavailability [2,3].
The present exploration was to increase the solubility of ECB by making 
solid dispersions using polyethylene glycol (PEG) carriers [4-8], namely 
PEG - 3350, PEG - 4000, PEG - 6000, PEG - 8000, and PEG - 20000 and 
finding out the best polymer among them. The solid dispersions were 
prepared by microwave melting method.
MATERIALS AND METHODS
Materials
ECB was procured from Yarrow Chemicals. PEG - 3350, PEG - 4000, 
PEG - 6000, PEG - 8000, and PEG – 20000 were obtained from Amrutha 
Organics, Hyderabad. Microcrystalline cellulose, talc, and magnesium 




Physical remarks of drug and excipients were studied by taking ECB 
and excipients in 1:1 ratio and compatibility studied at stressed 
storage conditions, i.e., at a temperature of 40°C and RH of 75% in 
environment control chamber [9] (Classic Scientific India, Mumbai) 
was performed.
Hygroscopic studies
The hygroscopic study of ECB was done under 33, 53, and 75% RH 
for 4 days and the weight gain was studied [10]. These studies were 
performed in triplicates.
Solubility studies
ECB was tested for solubility in 0.1 N HCl, water, pH 4.5 acetate buffer, 
pH 6.8 phosphate buffer, and pH 7.4 phosphate buffer [11].
Fabrication of solid dispersions
Solid dispersions with different drug:polymer ratios, from 1:1, 1:2, 1:4, 
and 1:6 w/w, were prepared using a microwave-induced fusion method. 
ECB and PEG 3350 were weighed in the ratio 1:1 and mixed gently for 
5 min using a mortar and pestle. A fixed amount (i.e., 2 g) of the mixture 
was subjected to microwave radiation for different durations (3, 4, 5, and 
6 min) at a constant power of 590 W in a microwave reactor (CATA-2R, 
Catalyst Systems, Pune, India). Similarly, mixtures of other ratios (from 
1:2, 1:4, and 1:6 w/w) were prepared. Only one beaker was placed 
at a time inside the microwave oven. Then, the beakers containing the 
samples were maintained at room temperature for the samples to solidify. 
The solid dispersions were collected and placed in a glass desiccator for 
24 h, and then, the product was pulverized using a mortar and pestle. The 
pulverized powders were passed through an 80# sieve. Same procedure 
is adopted using PEG - 4000, PEG - 6000, PEG - 8000, and PEG - 20000 
carriers. The various formulae of ECB with PEG are shown in Table 1.
Flow properties
The fabricated solid dispersions were evaluated for micromeritic 
properties [12,13].
Preparation of tablets containing the solid dispersion
The prepared tablets with solid dispersions equivalent to 60 mg of ECB 
were prepared by direct compression method [14] after mixing with the 
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required amount of different ingredients as shown in Table 2 using 8 station 
tablet compression machine (Karnavati Engineering, Ahmedabad, India).
Evaluation of solid dispersions of ECB
The following parameters were tested for ECB solid dispersions [15-18].
Morphological characteristics
In this study, tablets were tested for size and shape.
Thickness
Tablets were evaluated for their thickness using Vernier Calipers (Qumos 
Enterprises, Mumbai, India). These trails were made in triplicates.
Hardness
The force of fracture was recorded using Monsanto tablet hardness tester 
(Vinsyst Technologies, Mumbai). These tests were performed in triplicates.
Uniformity in weight
A total of 20 tablets from each formulation were weighed individually 
using an electronic digital balance (Citizen, CY-104, Mumbai) and 
calculated the average weight and compared with the individual tablet 
weights. From this, percentage weight difference was calculated and 
then checked for IP specifications (limit ± 7.5% of average weight).
Friability
It is the occurrence in which tablet surfaces are injured when subjected 
to physical tremor or erosion. This test was performed using Roche 
Friabilator. 20 tablets were weighed before the test (Winitial) and moved 
into a friabilator. The equipment was run at a speed of 25 rpm for the 
Table 1: Drug(ECB):carrier(PEG) ratios in various formulations
Drug: carrier Ratio Formulation name





















Table 2: Formulation of a tablet containing solid dispersions
Ingredients Quantity per 
tablet(mg)






The weight of the tablets 250
Table 3: ECB excipients(1:1) compatibility study physical observations
Binary mixture Initial Storage condition
Room temperature 40°C/75%RH
10 days 20 days 30 days 10 days 20 days 30 days
Etoricoxib White to off-white powder NCC NCC NCC NCC NCC NCC
E+PEG-3350 White waxy powder NCC NCC NCC NCC NCC NCC
E+PEG-4000 White waxy powder NCC NCC NCC NCC NCC NCC
E+PEG-6000 White waxy powder NCC NCC NCC NCC NCC NCC
E+PEG-8000 White waxy powder NCC NCC NCC NCC NCC NCC
E+PEG-20000 White waxy powder NCC NCC NCC NCC NCC NCC
E+Lactose Off-white powder NCC NCC NCC NCC NCC NCC
E+Starch Off-white powder NCC NCC NCC NCC NCC NCC
E+MCC Off-white powder NCC NCC NCC NCC NCC NCC
E+MS Off-white powder NCC NCC NCC NCC NCC NCC
E+Talc Off-white powder NCC NCC NCC NCC NCC NCC
E-Etoricoxib, PEG: Polyethylene glycol, MCC: Microcrystalline cellulose, MS: Magnesium stearate, ECB: Etoricoxib
Fig. 1: Solubility of etoricoxib at various media
Fig. 2: Solubility of etoricoxib and solid dispersions with 
PEG - 3350 in various media
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period of 4 min and the final weight of tablets (Wfinal) was determined. 
The percentage friability was then measured by the following equation:
F





Table 4: Hygroscopicity data(ECB)
Time interval % weight change
33% RH 53% RH 75% RH
Day 1 0.00 0.0 0.0
Day 2 0.00 0.01±0.001 0.02±0.001
Day 4 0.00 0.01±0.001 0.01±0.001
Equilibrium RH
Day 0 0.101±0.002
Day 4 0.113±0.001 0.115±0.003 0.117±0.002
Inference Non-hygroscopic
All values mentioned as mean±SD, the number of trials(n=3), ECB: Etoricoxib
Table 5: Flow character specifications
Formulation Flow properties
Angle of repose(0) LBD TBD CI HR
EPEG3-1 25.21±0.04 0.135±0.01 0.144±0.01 6.250±0.03 1.066±0.03
EPEG3-2 29.33±0.05 0.369±0.02 0.399±0.03 7.518±0.02 1.081±0.01
EPEG3-3 34.21±0.04 0.659±0.03 0.677±0.03 2.658±0.01 1.027±0.02
EPEG3-4 25.21±0.02 0.658±0.01 0.691±0.04 4.775±0.02 1.050±0.03
EPEG4-1 26.33±0.01 0.941±0.03 0.985±0.07 4.467±0.02 1.046±0.01
EPEG4-2 28.45±0.08 0.286±0.01 0.303±0.03 5.610±0.04 1.059±0.01
EPEG4-3 29.21±0.09 0.385±0.02 0.432±0.02 10.876±0.02 1.122±0.03
EPEG4-4 29.04±0.06 0.365±0.02 0.401±0.03 8.977±0.02 1.098±0.01
EPEG6-1 30.25±0.04 0.285±0.01 0.298±0.01 4.362±0.03 1.045±0.03
EPEG6-2 29.21±0.01 0.654±0.03 0.668±0.04 2.095±0.01 1.021±0.02
EPEG6-3 27.25±0.03 0.256±0.01 0.287±0.01 10.801±0.07 1.121±0.03
EPEG6-4 25.09±0.02 0.748±0.02 0.795±0.02 5.911±0.045 1.062±0.03
EPEG8-1 27.27±0.05 0.458±0.01 0.521±0.03 12.092±0.02 1.137±0.01
EPEG8-2 26.21±0.04 0.136±0.01 0.142±0.01 4.225±0.03 1.044±0.01
EPEG8-3 26.37±0.09 0.195±0.01 0.213±0.01 8.450±0.02 1.092±0.04
EPEG8-4 31.21±0.04 0.358±0.02 0.385±0.03 7.012±0.02 1.075±0.03
EPEG20-1 30.54±0.06 0.365±0.01 0.407±0.02 10.319±0.05 1.115±0.03
EPEG20-2 28.45±0.02 0.458±0.02 0.489±0.03 6.339±0.02 1.067±0.01
EPEG20-3 29.35±0.04 0.526±0.04 0.536±0.03 1.865±0.01 1.019±0.01
EPEG20-4 27.97±0.05 0.956±0.07 0.978±0.03 2.249±0.02 1.023±0.03
LBD: Loose bulk density, TBD: Tapped bulk density, CI: Carr’s index, HR: Hausner’s ratio, All values mentioned as mean±SD; the number of trials(n=3)








Friability (%) Yield(%) Assay(%)
EPEG3-1 4.5±0.02 4.5±0.01 253.1±0.03 0.51±0.05 97.5±0.06 98.6±2.33
EPEG3-2 4.5±0.08 5.2±0.05 254.3±0.01 0.41±0.02 98.3±0.05 99.4±0.01
EPEG3-3 4.6±0.05 7.3±0.01 250.2±0.02 0.33±0.01 99.6±0.06 98.9±0.06
EPEG3-4 4.51±0.01 5.3±0.04 251.2±0.01 0.36±0.01 99.8±0.06 97.6±5.24
EPEG4-1 4.53±0.02 4.5±0.02 255.1±0.03 0.51±0.08 92.1±0.06 96.3±0.95
EPEG4-2 4.50±0.03 5.2±0.02 250.9±0.01 0.17±0.01 95.3±0.06 99.2±2.38
EPEG4-3 4.51±0.01 6.3±0.07 252.3±0.01 0.52±0.05 94.6±0.06 100.9±6.35
EPEG4-4 4.53±0.07 5.3±0.01 253.8±0.02 0.25±0.02 96.8±0.06 97.6±0.09
EPEG6-1 4.50±0.02 4.5±0.03 250.5±0.01 0.44±0.05 97.2±0.06 98.3±0.09
EPEG6-2 4.51±0.05 5.2±0.02 250.1±0.03 0.85±0.08 97.5±0.06 99.0±0.01
EPEG6-3 4.53±0.09 6.7±0.01 254.2±0.01 0.53±0.02 96.3±0.06 102.1±0.01
EPEG6-4 4.50±0.08 8.3±0.01 252.2±0.02 0.25±0.02 96.9±0.06 99.2±0.08
EPEG8-1 4.51±0.01 4.5±0.03 250.3±0.01 0.15±0.01 97.8±0.06 96.5±0.95
EPEG8-2 4.53±0.02 5.2±0.09 252.6±0.02 0.62±0.05 98.4±0.06 97.5±0.01
EPEG8-3 4.50±0.05 7.3±0.01 251.2±0.02 0.56±0.04 98.6±0.06 99.2±2.38
EPEG8-4 4.51±0.06 5.3±0.02 250.5±0.01 0.25±0.08 97.3±0.06 98.2±0.15
EPEG20-1 4.52±0.02 4.5±0.02 250.3±0.01 0.54±0.01 98.2±0.06 100.1±0.08
EPEG20-2 4.50±0.08 5.9±0.07 251.2±0.01 0.62±0.02 97.6±0.06 97.3±0.15
EPEG20-3 4.51±0.05 6.3±0.01 250.1±0.05 0.53±0.08 94.1±0.06 98.5±0.09
EPEG20-4 4.51±0.01 5.3±0.01 252.1±0.01 0.63±0.04 97.3±0.06 97.9±0.81
All values mentioned as mean±SD; the number of trials(n=3)
Fig. 3: Solubility of etoricoxib and solid dispersions with 
PEG - 4000 in various media
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Yield
The percentage recovery of formulated solid dispersion was resolute 
after complete removal of moisture. Thus, percentage recovery 
calculation involves the weight of dried solid dispersion to sum of the 
weight of drug and pharmaceuticals required for the formulation.
Actual weight of the solid dispersions
% Yield  
Total weight of drug and excipients 
100= ×
Uniformity of drug content
Five tablets from each batch were taken and weighed and powdered 
in crushed in mortar and pestle. A weight equal to 60 mg of ECB was 
dissolved in 100 ml of 0.1 N HCl (pH 1.2). From this, 0.2 ml sample 
was withdrawn and diluted to 10 ml with 0.1 N HCl. The absorbance 
was determined [19] at 233 nm with double-beam UV-visible 
spectrophotometer (Lab India, Mumbai). Content uniformity was 
calculated from ECB standard graph.
ECB calibration curve
The process of determining ECB by UV spectrophotometer at 233 nm 
was standardized and the drug was found to obey Beer–Lambert’s law 
in 2–12 µg/ml concentration [20].
Dissolution rate/in vitro drug release
The dissolution specifications were as below [21].








All values mentioned as mean±SD; number of trials(n=3), ECB: Etoricoxib
Fig. 4: Solubility of etoricoxib and solid dispersions with 
PEG - 6000 in various media
Fig. 5: Solubility of etoricoxib and solid dispersions with 
PEG - 8000 in various media
Fig. 6: Solubility of etoricoxib and solid dispersions with 
PEG - 20000 in various media
Fig. 7: Calibration curve for the estimation of etoricoxib
Fig. 8: In vitro drug dissolution plots of etoricoxib and PEG - 3350 
solid dispersions
Fig. 9: In vitro drug dissolution plots of etoricoxib and PEG - 4000 
solid dispersions
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Kinetic modeling of drug release
The mechanism of the drug release was analyzed and rate kinetics of 





Accelerated stability studies of ECB solid dispersions
The evaluated ECB solid dispersions were then subjected to 
stability studies for a period of 3 months under stressed storage 
conditions [24].
RESULTS
The compatibility study revealed that ECB was found to compatible 
with the excipients used and they are tabulated in Table 3.
Physical observations of excipients compatibility study at stressed 
storage conditions
The hygroscopic study of ECB at room temperature (25±2°C) and 
humidity conditions is shown in Table 4.
The solubility of ECB pure drug in various solvents is shown in Fig. 1.
The fabricated ECB solid dispersions were characterized for flow 
properties and the values are shown in Table 5.
Evaluation of ECB solid dispersions (in tablet dosage form)
The fabricated ECB solid dispersions tablets were observed for 
physicochemical characteristics and they are tabulated in Table 6.
Solubility studies of ECB solid dispersions
The solubility of ECB and prepared ECB solid dispersions are shown in 
Figs. 2-6.
Calibration curve of ECB
The calibration curve of ECB is shown in Table 7 and Fig. 7.
Dissolution data of ECB from PEG solid dispersions
The dissolution of prepared tablets was found good in formulations 
containing ECB:PEG ratios 1:4. These are shown in Figs. 8–12.
Kinetic modeling of drug release
The drug release mechanism from prepared tablets formulations was 
determined by kinetic treatment of in vitro drug dissolution data. The 
Fig. 12: In vitro drug dissolution plots of etoricoxib and 
PEG - 20000 solid dispersions
Fig. 13: First-order plots for EPEG tablets
Fig. 14: Hixson–Crowell’s plots for EPEG-4 tablets
Fig. 10: In vitro drug dissolution plots of etoricoxib and 
PEG - 6000 solid dispersions
Fig. 11: In vitro drug dissolution plots of etoricoxib and 
PEG - 8000 solid dispersions
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correlation (r2) values from the different kinetics equations were 
shown in Figs. 13 and 14.
DISCUSSION
The compatibility study revealed that ECB was found to compatible 
with the excipients used. The hygroscopicity study of the drug used 
ECB indicates that drug is non-hygroscopic, as the percentage weight 
increase in the samples at the study was <0.2%.
ECB pure drug showed good solubility in 0.1 N HCl 
(0.325±0.0011 µg/ml) and water (0.212±0.0021 µg/ml). The 
solubility of ECB was found to be 0.212±0.0023, 0.125±0.0051, and 
0.185±0.0065 µg/ml in pH 4.5 acetate buffer, pH 6.8 phosphate buffer, 
and pH 7.4 phosphate buffer, respectively. The solubility data indicate 
that ECB has very poor solubility. The fabricated ECB solid dispersions 
were found to have excellent flow properties.
The fabricated ECB solid dispersion tablets were observed to have a 
uniform in size, shape, off-white in color, and odorless with smooth 
surface. The prepared tablets were found to have a uniform thickness 
(4.5 mm) and weight. The loss on friability was <1% and the hardness 
was more than 4 kg/cm2 indicating that the prepared tablets having good 
mechanical strength. The percentage yield of solid dispersions was found 
to good (>90%) and the drug content was also found to be uniform.
The solubility of prepared tablets was found good in distilled water 
and 0.1 N HCl. All the ECB solid dispersion batches with PEG - 3350 
showed good solubility in distilled water (up to 1.99±0.01 µg/ml) 
and 0.1 N HCl (up to 1.75±0.02 µg/ml). All the ECB solid dispersion 
batches with PEG - 4000 showed good solubility in distilled water (up 
to 1.78±0.01 µg/ml) and 0.1 N HCl (up to 1.24±0.01 µg/ml).
All the ECB solid dispersion batches with PEG - 6000 showed good 
solubility in distilled water (up to 1.21±0.01 µg/ml) and 0.1 N HCl (up 
to 0.81±0.01 µg/ml).
All the ECB solid dispersion batches with PEG - 80000 showed good 
solubility in distilled water (up to 2.25±0.09 µg/ml), in PBS (pH 7.5) (up 
to 1.98±0.05 µg/ml), and in 0.1 N HCl (up to 1.85±0.03 µg/ml).
All the solid dispersion batches of PEG - 20000 showed good solubility 
in 0.1 N HCl (up to 1.98±0.07 µg/ml) and distilled water (up to 
1.87±0.01 µg/ml). The dissolution of prepared tablets was found good 
in all the formulations containing ECB.
The drug release mechanism from prepared tablets formulations was 
determined by kinetic treatment of in vitro drug dissolution data. The 
correlation (r2) values from the different kinetics equation revealed 
that the drug release from the prepared solid dispersions was found to 
follow different models, but the best fit model was selected. First order 
and Hixson Crowell’s plots. The optimized formulation (EPEG6-4) when 
subjected to accelerate stability studies, it retained its drug content, 
hardness, and cumulative percentage drug release.
CONCLUSION
This investigation was performed to the best PEG carrier for preparing 
solid dispersions by taking ECB as a model drug. The formulation 
EPEG6-4 in the ratios 1:6 was found to have good solubility and 
drug dissolution characteristics. Moreover, among the PEG - 3350, 
PEG - 4000, PEG - 6000, PEG - 8000, and PEG - 20000, polyethylene 
glycol was found to be the best PEG among the tested one as solid 
dispersion carrier.
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